Mar 3, 2026 03:15PM
Mar 3, 2026 07:02AM
Mar 3, 2026 07:00AM
Mar 2, 2026 04:05PM
Feb 17, 2026 07:00AM
Feb 3, 2026 05:00AM
Nov 18, 2025 07:01AM Harrow completes acquisition of Melt Pharmaceuticals for sedation therapies
Nov 18, 2025 07:00AM
Nov 10, 2025 04:05PM
Oct 6, 2025 07:00AM
Oct 6, 2025 07:00AM
Sep 26, 2025 07:00AM
Sep 26, 2025 07:00AM
Sep 23, 2025 06:45AM Harrow Health (HROW) PT Raised to $70 at B.Riley
Aug 11, 2025 04:01PM
Jul 17, 2025 07:00AM
Jul 17, 2025 07:00AM
Jul 17, 2025 07:00AM
Jun 11, 2025 04:25PM
Jun 9, 2025 07:03AM
Jun 9, 2025 07:00AM Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
May 8, 2025 04:01PM
Apr 10, 2025 07:00AM
Mar 27, 2025 04:01PM
Mar 24, 2025 07:05AM
Mar 24, 2025 07:00AM
Mar 11, 2025 07:00AM
Feb 6, 2025 08:44AM H.C. Wainwright Starts Harrow Health (HROW) at Buy
Jan 7, 2025 07:01AM
Jan 7, 2025 07:00AM
Nov 22, 2024 01:51PM
Nov 20, 2024 07:00AM
Oct 18, 2024 06:10AM
Oct 10, 2024 07:00AM
Oct 3, 2024 07:02AM Harrow Health (HROW) Relaunches TRIESENCE
Oct 3, 2024 07:00AM
Jul 29, 2024 08:00AM
Jul 9, 2024 07:02AM
Jul 9, 2024 07:00AM
Jun 20, 2024 07:04AM
Jun 20, 2024 07:00AM
Jun 6, 2024 08:00AM Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Jun 5, 2024 07:00AM
Apr 2, 2024 08:16AM
Jan 11, 2024 07:02AM
Jan 11, 2024 07:00AM
Jan 3, 2024 07:15AM
Oct 24, 2023 07:00AM
Sep 26, 2023 08:00AM Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
Aug 9, 2023 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All